The clinical observation of Jianpibushen formula in subclinical hypothyroidism associated with osteoporosis patients of spleen kidney yang deficiency

Objective To observe the clinical observation of Jianpibushen formula in subclinical hypothyroidism (SCH) associated with osteoporosis (OP) patients of spleen kidney yang deficiency. Methods From January 2015 to January 2017, 120 SCH with OP patients were randomly divided into the research group and the control group according to the random number table. The control group were given the conventional radiation of improving the thyroid gland and osteoporosis treatment. While the research group were given Jianpibushen formula on the basis of the control group. After one year treatment, thyroid function, bone metabolism, cytokine, bone mineral density (BMD), symptom score, curative effect and adverse reaction were compared between the two groups. Results After treatment, TSH [(3.01±0.42) mU/L], PTH: [(18.75±4.39) ng/L], bone metabolism [BGP: (12.92±4.39) ng/mL, PINP: (240.79±9.38) μg/L, CTX (0.23±0.01)mmol/L], cytokine [IL-10: (2.63±1.07) pg/mL, IL-6: (85.71±9.25) pg/mL], symptom score[(21.45±4.33) scores], and curative effect(84.0%) in the research group were significantly better than those in the control group. The differences were statistically significant (all P<0.05). Conclusion Thyroid function was an important factor on affecting bone metabolism. SCH can cause bone loss and reduce the BMD. Combing the Jianpibushen formula with the conventional treatment of SCH with OP patients of spleen kidney yang deficiency had satisfaction curative effect. It can significantly improve the thyroid function, promoting the bone formation, decreasing the bone resorption, increasing the BMD, and improving clinical symptoms and curative effect.